Sarepta therapeutics announces partnership with roche in territories outside the united states

Sarepta therapeutics announces partnership with roche in territories outside the united states for its investigational micro-dystrophin gene therapy for duchenne muscular dystrophy, srp-9001.sarepta therapeutics - to receive upfront payment of $1.15 billion, comprising $750 million in cash and $400 million in sarepta stock, priced at $158.59 per share.
SRPT Ratings Summary
SRPT Quant Ranking